Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-
April 06, 2026
Melinda French Gates donates $215 million to improve women's health worldwide
SK Hynix tells investors its US listing plan wins their strong backing, source says
Serbia's security agency advises Vucic not to travel to EU summit in Montenegro
Artists threaten legal action against Venice Biennale over inclusion in visitors' ballot
India's Modi meets Delcy Rodriguez as India expands Venezuela oil imports
Iran's Khamenei warns against divisions after 'enemy's defeat on battlefield'
Australia's Lynas Rare Earths names Pol Le Roux interim CEO
Broadcom tumbles as revenue miss clouds AI boom bets
Sherpa rescued after going missing on Everest with no food, oxygen
Fan runs onto court to take selfie with ‘surprised’ Victor Wembanyama during NBA Finals Game 1